English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45073/58249 (77%)
造訪人次 : 2401422      線上人數 : 162
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/57515


    題名: 探討生存素在肝癌治療上的角色
    The role of survivin in the treatment of hepatocellular carcinoma
    作者: 洪進昇
    Hung, Chin-Sheng
    關鍵詞: 生存素;肝癌;自我凋亡;小干擾核醣核酸;薑黃素;化學治療;survivin;hepatocellular carcinoma;apoptosis;siRNA;curcumin;chemotherapy
    日期: 2013-01-19
    上傳時間: 2019-05-29 09:47:55 (UTC+8)
    摘要: 肝癌一直是國人惡性腫瘤死因的第一順位,除了與B型肝炎的盛行率高有關外,治療上大約只有30%的肝癌患者可以接受手術切除,手術後的高復發率以及藥物治療效果不佳,使得肝癌的治療一直是個難題。生存素(survivin)是一個抑制細胞自我凋亡的蛋白質,近年來由於它只在腫瘤組織中高度表現的特性,使得生存素成為一個理想的治療目標。生存素在肝癌上的表現與藥物治療效果的相關性,目前了解的仍有限。所以,本研究主要目標是探討生存素在肝癌藥物治療上的角色,並進而發展個人化的癌症治療。
    藉由小干擾RNA(siRNA)的技術降低生存素的表現量,進一步探討生存素表現量對於藥物作用下的影響。我們利用細胞存活分析(MTT assay)發現生存素表現量降低時,Mahlavu及HepJ5兩株肝癌細胞都對Gemcitabine的藥物感受性升高,而在流式細胞儀的細胞自我凋亡及細胞週期分析也發現,Gemcitabine在生存素表現量低的細胞會讓更多的細胞進到自我凋亡。進一步朝細胞的內質網壓力及藥物效果方面去探討,發現生存素的表現與GRP78有關,生存素表現量降低時,GRP78的表現量也降低,也因此有較好的毒殺效果。相反的,在薑黃素(curcumin)對於肝癌的治療效果上,卻是生存素表現量高,curcumin作用的效果才好。細胞存活率分析發現,生存素表現量高的細胞對curcumin作用感受性高,造成較多的細胞進入自我凋亡,生存素表現量低會使curcumin造成細胞自我凋亡的效果明顯減少。進一步分析自我凋亡的相關分子發現,生存素表現量降低後,Bcl-2及BAX對薑黃素作用所造成的影響明顯降低。
    我們的研究顯示,生存素表現量與藥物治療效果之間有著密切的關係,並且隨著藥物的不同所得到的結果會不一樣,並且我們也發現生存素的表現量與細胞的內質網壓力有關,生存素經由GRP78的作用來影響Gemcitabine藥物在肝癌上治療的效果。應用到臨床上,腫瘤組織的生存素表現量可以作為藥物治療前的指標,在肝癌的藥物治療可以作為選擇適當藥物治療的參考,增加治療的效果。若是生存素表現量低的肝癌,就使用Gemcitabine針對腫瘤的DNA合成加以抑制,可能獲得較好的治療效果。若是表現量高的肝癌,則可以使用薑黃素治療,造成更多的癌細胞自我凋亡。因此,我們的研究提供了未來發展的方向,將來可以藉生存素的表現量選擇治療的藥物,發展個人化的治療。

    Hepatocellular carcinoma (HCC) is the most common malignancy in Taiwan and results in many cancer deaths. The most important risk factor is the prevalence of hepatitis B virus infection. Only about 30% patients with HCC could receive operations as curative treatment. High recurrence rate and poor response of medical treatment make the treatment of HCC a difficult problem. Survivin is an antiapoptotic molecule that is widely expressed in cancers, including hepatocellular carcinoma. Survivin has become a general therapeutic target for cancers because of its selective overexpression in a majority of tumors. However, little is known regarding the effect of survivin expression in the drug therapeutic efficacy on HCC.
    We generated survivin knockdown cells (survivin-KD) via a short interfering RNA (siRNA) technique. The anti- proliferation effects of gemcitabine and curcumin were determined by MTT assay, fluorescence microscopy, TUNEL assay, and cell cycle evaluation. According to the MTT assay, we found that survivin-KD cells were more sensitive than parental cells and scrambled control cells to gemcitabine treatment. The apoptotic cell population increased in survivin-KD cells while treating with gemcitabine in comparison to scrambled control cells, as observed by the cell cycle distribution and TUNEL assays. We further identified that therapeutic efficacy of gemcitabine may be through GRP78. But, controversially, survivin-KD cells were resistant to curcumin treatment. In curcumin treatment, we noted the phenomenon of better therapeutic efficacy in scrambled control cells than survivin-KD cells. The resistance of curcumin after survivin suppression resulted from the modulation of Bcl-2 and BAX expression.
    Our study results showed that the expression level of survivin may be a potential marker to predict the therapeutic efficacy of anti-neoplastic drugs in HCC. The relationship between survivin and endoplasmic reticulum stress is a novel finding and provides us a new direction for further research. In clinical practice, gemcitabine may be a good choice of chemotherapy regiments in HCC with low survivin expression level. However, patients with HCC of high survivin expression level could choose curcumin as adjuvant treatment. From our research results, survivin could be an effective biomarker in developing personalized cancer treatment in the future.
    描述: 博士論文
    指導教授-張育嘉
    共同指導教授-魏柏立
    委員-賴逸儒
    委員-林豐彥
    委員-陳俊憲
    委員-陳裕仁
    委員-黃銘德
    資料類型: thesis
    顯示於類別:[臨床醫學研究所] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML109檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋